To determine whether lead autophagy activators identified in control neurons were effective in tauopathy neurons and promoted tau clearance, FTD patient-derived neurons expressing tau-A152T21,31 or tau-P301L37,44 were employed (Fig. 1f). The gene discussed is MAPT; the disease is frontotemporal dementia.